Descriptive Analysis Of Patients With Psoriasis (PSO) Using Biologics Vs. Non-biologics
Author(s)
Sahar Syed, BS1, Staci Bell, MS2, Krisha Patel, BS, MPH1, Mohammed Deeb, MD1, Scott Chavers, PhD1;
1Walgreens Real World Evidence Clinical Trials, Pharmacoepidemiology, Deerfield, IL, USA, 2Walgreens Real World Evidence Clinical Trials, Data Sciences, Deerfield, IL, USA
1Walgreens Real World Evidence Clinical Trials, Pharmacoepidemiology, Deerfield, IL, USA, 2Walgreens Real World Evidence Clinical Trials, Data Sciences, Deerfield, IL, USA
Presentation Documents
OBJECTIVES: Patients may use treatment options including biologics and non-biologics to treat plaque psoriasis. Biologics are more expensive than non-biologics which may be a barrier to treatment. This research aims to describe the demographic characteristics, healthcare utilization, and costs among patients with psoriasis who use biologics vs non-biologics
METHODS: This study utilized pharmacy data from the Walgreens Retail Pharmacy Database. Participants with psoriasis with a prescription for biologics or non-biologics were identified between January 1, 2023, and December 31, 2023. No statistical comparisons were conducted as this study was descriptive.
RESULTS: There were 3,582 individuals with psoriasis who used biologics vs. 170,212 individuals who used non-biologics in the pharmacy data. Individuals who used non-biologics were slightly older than those who used biologics (56 years vs. 52 years). 56.8% of those using non-biologics were male vs. 44.8% of those using biologics. Over 50% of participants in both groups were White. Most participants using non-biologics were from the South (39.8%) vs. 40.8% of participants using biologics either had missing regional data or were from Puerto Rico. 91,741 (52.3%) of participants using non-biologics had commercial insurance vs.1,078 (25.6%) of participants using biologics who used commercial insurance as their primary insurance. Notably, 50% of participants using biologics had a government insurance type as their primary insurance. Distributions of provider type among both groups were similar. However, more participants using biologics saw a rheumatologist compared to those using non-biologics (41.9% vs 29.2%). Biologic users incurred a median monthly out-of-pocket cost of $27.48 compared to $14.49 for non-biologic users.
CONCLUSIONS: Individuals who used biologics were slightly younger, more likely to be female, overwhelmingly used the government insurance type, had more rheumatologist visits, and had higher median out-of-pocket costs. This research underscores the possible impact of insurance type, utilization, and costs on differences in plaque psoriasis treatment.
METHODS: This study utilized pharmacy data from the Walgreens Retail Pharmacy Database. Participants with psoriasis with a prescription for biologics or non-biologics were identified between January 1, 2023, and December 31, 2023. No statistical comparisons were conducted as this study was descriptive.
RESULTS: There were 3,582 individuals with psoriasis who used biologics vs. 170,212 individuals who used non-biologics in the pharmacy data. Individuals who used non-biologics were slightly older than those who used biologics (56 years vs. 52 years). 56.8% of those using non-biologics were male vs. 44.8% of those using biologics. Over 50% of participants in both groups were White. Most participants using non-biologics were from the South (39.8%) vs. 40.8% of participants using biologics either had missing regional data or were from Puerto Rico. 91,741 (52.3%) of participants using non-biologics had commercial insurance vs.1,078 (25.6%) of participants using biologics who used commercial insurance as their primary insurance. Notably, 50% of participants using biologics had a government insurance type as their primary insurance. Distributions of provider type among both groups were similar. However, more participants using biologics saw a rheumatologist compared to those using non-biologics (41.9% vs 29.2%). Biologic users incurred a median monthly out-of-pocket cost of $27.48 compared to $14.49 for non-biologic users.
CONCLUSIONS: Individuals who used biologics were slightly younger, more likely to be female, overwhelmingly used the government insurance type, had more rheumatologist visits, and had higher median out-of-pocket costs. This research underscores the possible impact of insurance type, utilization, and costs on differences in plaque psoriasis treatment.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE511
Topic
Economic Evaluation
Disease
SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain), STA: Biologics & Biosimilars